Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer

• Amanee D Salaam,
• Patrick Hwang,
• Roberus McIntosh,
• Hadiyah N Green,
• Ho-Wook Jun and
• Derrick Dean

Beilstein J. Nanotechnol. 2014, 5, 937–945, doi:10.3762/bjnano.5.107

• work, we developed a novel ND meditated drug delivery system to increase specificity of DOX by utilizing DGEA to target the α2β1 integrins overexpressed in metastatic prostate cancers. ND-DGEA conjugates and the ND-DGEA+DOX system were synthesized and evaluated for multifunctional applications (i.e

• effects of the drug delivery system were due to the combination of enhanced targeting and drug delivery instead of potential toxicity of ND or DGEA peptide, PC3 cells were also exposed to ND, ND-DGEA, and free DGEA. The cell viability was quantified with a 3-(4,5-dimethylthiazol-2-yl)-5-(3

• drug concentrations, DOX efficacy was enhanced. The quantitative analysis of DOX release kinetics and cellular internalization are limitations of this study and should be the subject of future studies. Conclusion In this study, a novel targeted drug delivery system consisting of NDs (drug delivery